

## **Eiger BioPharmaceuticals to Present at Biotech Showcase™ 2018**

**PALO ALTO, Calif. – January 2, 2018** – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory, President and CEO, will present a corporate update at Biotech Showcase™ 2018 on January 8th at 2:00 pm PT at the Hilton San Francisco (Franciscan – B Ballroom Level). The corporate update will include a discussion of recent progress across all Eiger programs including Hepatitis Delta Virus (HDV), Pulmonary Arterial Hypertension (PAH), Post-Bariatric Hypoglycemia (PBH) and Lymphedema.

A live webcast of the presentation will be available on the Eiger BioPharmaceuticals website at [www.eigerbio.com](http://www.eigerbio.com) under the “Investors” tab. A replay of the webcast will be available approximately one hour following the completion of the live event.

Eiger will host 1:1 meetings at the Sir Francis Drake Hotel (450 Powell Street), a block away from the JP Morgan Conference venue at Union Square.

### **About Eiger**

Eiger is a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for orphan diseases. We are committed to translational innovation and the repurposing of well-characterized drugs acting on newly identified or novel targets. Our mission is to systematically reduce the time and cost of the drug development process to more rapidly deliver important medicines to patients with orphan diseases. For additional information about Eiger and its clinical programs, please visit [www.eigerbio.com](http://www.eigerbio.com).



Investors: Ingrid Choong, PhD  
Eiger BioPharmaceuticals, Inc.  
1-650-619-6115, [ichoong@eigerbio.com](mailto:ichoong@eigerbio.com)